Scholarlink

<p>In this study the discrepancies in dose estimations from a <sup>90</sup>Y-filled hepatopulmonary shunt phantom (HPSP) were analyzed using SPECT/CT, PET/CT, and PET/MR modalities. The dose variability was also evaluated among randomly selected individuals undergoing <sup>90</sup>Y-microsphere therapy. The HPSP comprised a right lung of 1,101&#xa0;cm³, a left lung of 863&#xa0;cm³, a healthy liver parenchyma of 690&#xa0;cm³, and two intrahepatic tumours of 202&#xa0;cm³ and 9.5&#xa0;cm³. <sup>90</sup>Y-chloride activity was diluted in water and injected into the phantom. SPECT/CT, PET/CT, and PET/MR were acquired with the phantom immersed in water. Absorbed dose was calculated for phantom compartments and for patients with liver tumours who were treated with <sup>90</sup>Y-glass microspheres. The calculated lung shunt fraction (LSF) (12.0%) from the PET/MR images was closest to the actual LSF (11.03%), followed by PET/CT with 12.2% and SPECT/CT with 13.4% LSF. The deviation between the actual dose estimates and <sup>90</sup>Y-PET/MR was − 0.1% for the large tumour (202&#xa0;cm³), -10.5% for the small tumour (9.5&#xa0;cm³), -7.5% for the healthy liver parenchyma, and 6.1% for the lung. For <sup>90</sup>Y-PET/CT, the deviation was 4.8% for the large tumour, -7.5% for the small tumour, -15.5% for the healthy liver parenchyma, and 7.6% for the lung. In contrast, a significant disparity was observed in the <sup>90</sup>Y-SPECT/CT modality, with deviations of -6.3% for the large tumour, -65.3% for the small tumour, -10.7% for the healthy liver parenchyma, and 18.2% for the lung. In the patient study, the doses from <sup>99m</sup>Tc-MAA SPECT/CT and <sup>90</sup>Y-PET/MR images were comparable, whereas <sup>90</sup>Y-SPECT/CT yielded significantly lower dose estimates. The findings obtained demonstrate that <sup>90</sup>Y-SPECT/CT generates significant inaccuracies in absorbed dose estimates mainly for small tumours. All modalities overestimated LSF and lung dose by less than 10% except SPECT/CT (18%). It is concluded that implementing an optimal imaging technique with robust scatter correction would mitigate the dose underestimate. <sup>90</sup>Y-PET/CT and <sup>90</sup>Y-PET/MR are the preferred methods for reliable dosimetry and precise dose–response assessment, especially owing to their robust correlation with <sup>99m</sup>Tc-MAA SPECT/CT simulation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cross-modality validation of quantitative 90Y imaging using a custom hepatopulmonary shunt phantom and patient data

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Nami Yeyin,
  • Mohammad Abuqbeitah,
  • Mustafa Demir,
  • Sinem Akyol,
  • Duygu Tunçman Kayaokay,
  • F. Fatih Kesmezacar,
  • Osman Günay,
  • Ghada ALMisned,
  • Bashar Issa,
  • H. O. Tekin

摘要

In this study the discrepancies in dose estimations from a 90Y-filled hepatopulmonary shunt phantom (HPSP) were analyzed using SPECT/CT, PET/CT, and PET/MR modalities. The dose variability was also evaluated among randomly selected individuals undergoing 90Y-microsphere therapy. The HPSP comprised a right lung of 1,101 cm³, a left lung of 863 cm³, a healthy liver parenchyma of 690 cm³, and two intrahepatic tumours of 202 cm³ and 9.5 cm³. 90Y-chloride activity was diluted in water and injected into the phantom. SPECT/CT, PET/CT, and PET/MR were acquired with the phantom immersed in water. Absorbed dose was calculated for phantom compartments and for patients with liver tumours who were treated with 90Y-glass microspheres. The calculated lung shunt fraction (LSF) (12.0%) from the PET/MR images was closest to the actual LSF (11.03%), followed by PET/CT with 12.2% and SPECT/CT with 13.4% LSF. The deviation between the actual dose estimates and 90Y-PET/MR was − 0.1% for the large tumour (202 cm³), -10.5% for the small tumour (9.5 cm³), -7.5% for the healthy liver parenchyma, and 6.1% for the lung. For 90Y-PET/CT, the deviation was 4.8% for the large tumour, -7.5% for the small tumour, -15.5% for the healthy liver parenchyma, and 7.6% for the lung. In contrast, a significant disparity was observed in the 90Y-SPECT/CT modality, with deviations of -6.3% for the large tumour, -65.3% for the small tumour, -10.7% for the healthy liver parenchyma, and 18.2% for the lung. In the patient study, the doses from 99mTc-MAA SPECT/CT and 90Y-PET/MR images were comparable, whereas 90Y-SPECT/CT yielded significantly lower dose estimates. The findings obtained demonstrate that 90Y-SPECT/CT generates significant inaccuracies in absorbed dose estimates mainly for small tumours. All modalities overestimated LSF and lung dose by less than 10% except SPECT/CT (18%). It is concluded that implementing an optimal imaging technique with robust scatter correction would mitigate the dose underestimate. 90Y-PET/CT and 90Y-PET/MR are the preferred methods for reliable dosimetry and precise dose–response assessment, especially owing to their robust correlation with 99mTc-MAA SPECT/CT simulation.